鍙傝€冩枃鐚�<\/b><\/span><\/p> <\/td> \n <\/tr> \n

[1] 浣滀负瀹屾暣娌荤枟鏂规鐢ㄤ簬浠ヤ笅涓ょ被瀵规湰鍝佷换涓€鎴愬垎鏃犲凡鐭ヨ€愯嵂鐩稿叧绐佸彉鐨�1鍨嬩汉绫诲厤鐤己闄风梾姣掞紙HIV-1锛夋劅鏌撴垚浜哄強12宀佷互涓婇潚灏戝勾锛堜綋閲嶈嚦灏�40鍏枻锛夋偅鑰咃細锛�1锛夋棤鎶楅€嗚浆褰曠梾姣掓不鐤楀彶鐨勬偅鑰咃紱锛�2锛変綔涓烘浛浠ｆ不鐤楁柟妗堬紝鐢ㄤ簬鎺ュ彈绋冲畾鎶楅€嗚浆褰曟不鐤楄揪鍒扮梾姣掑鎶戝埗锛圚IV-1 RNA锛�50鎷疯礉\/mL锛変笖鏃犳不鐤楀け璐ュ彶鐨勬偅鑰呫€�<\/span><\/p> <\/td> \n <\/tr> \n

[2] 涓崕鍖诲浼氭劅鏌撶梾瀛﹀垎浼氳壘婊嬬梾涓欏瀷鑲濈値瀛︾粍锛屼腑鍥界柧鐥呴闃叉帶鍒朵腑蹇冿紝涓浗鑹炬粙鐥呰瘖鐤楁寚鍗楋紙2021骞寸増锛塠J].涓浗鑹炬粙鐥呮€х梾锛�2021锛�27锛�11锛夛細1182-1201.<\/span><\/p> <\/td> \n <\/tr> \n

[3] CahnP, MaderoJS, ArribasJR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143鈥�155.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p>"]; $("#dvExtra").html(content_array[0]);})();